PL354540A1 - Drugs for the treatment of malignant tumours - Google Patents
Drugs for the treatment of malignant tumoursInfo
- Publication number
- PL354540A1 PL354540A1 PL00354540A PL35454000A PL354540A1 PL 354540 A1 PL354540 A1 PL 354540A1 PL 00354540 A PL00354540 A PL 00354540A PL 35454000 A PL35454000 A PL 35454000A PL 354540 A1 PL354540 A1 PL 354540A1
- Authority
- PL
- Poland
- Prior art keywords
- drugs
- treatment
- malignant tumours
- tumours
- malignant
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9903838A SE9903838D0 (en) | 1999-10-25 | 1999-10-25 | Novel compounds |
| SE0002320A SE0002320D0 (en) | 1999-10-25 | 2000-06-21 | Malignant tumors |
| PCT/SE2000/002055 WO2001030758A1 (en) | 1999-10-25 | 2000-10-24 | Drugs for the treatment of malignant tumours |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL354540A1 true PL354540A1 (en) | 2004-01-26 |
| PL199781B1 PL199781B1 (en) | 2008-10-31 |
Family
ID=31980718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL354540A PL199781B1 (en) | 1999-10-25 | 2000-10-24 | Drugs for the treatment of malignant tumours |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US6395750B1 (en) |
| CN (1) | CN100390148C (en) |
| PL (1) | PL199781B1 (en) |
| RS (1) | RS51019B (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10153347A1 (en) * | 2001-10-29 | 2003-05-08 | Gruenenthal Gmbh | Substituted 1H-quinolin-2-one compounds |
| SE0400235D0 (en) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| CA2881078C (en) | 2004-06-24 | 2018-10-02 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| BRPI0617477A2 (en) * | 2005-10-19 | 2011-07-26 | Teva Pharma | mixture of crystalline particles of sodium laquinimod, composition, process of crystallization of laquinimod sodium, laquinimod sodium, and process for producing a pharmaceutical composition |
| WO2007075901A2 (en) * | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of abc transporters |
| LT1993360T (en) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| CN101466379B (en) | 2006-06-12 | 2012-10-31 | 泰华制药工业有限公司 | Formulations of stable laquinimod |
| WO2009082471A1 (en) * | 2007-12-20 | 2009-07-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| AU2009288108B2 (en) * | 2008-09-03 | 2013-10-17 | Teva Pharmaceutical Industries, Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| SI3330255T1 (en) | 2009-03-20 | 2021-03-31 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| BR112012002124A2 (en) * | 2009-07-30 | 2015-09-15 | Teva Pharma | treatment of crohn's disease with laquinimode. |
| WO2011019375A1 (en) * | 2009-08-10 | 2011-02-17 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| EA201290860A1 (en) * | 2010-03-03 | 2013-04-30 | Тева Фармасьютикал Индастриз Лтд. | TREATMENT OF RHEUMATOID ARTHRITIS BY COMBINATION OF LAKVINIMODA AND METHOREXAT |
| KR20130006640A (en) * | 2010-03-03 | 2013-01-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | Treatment of lupus nephritis using laquinimod |
| US20110217295A1 (en) * | 2010-03-03 | 2011-09-08 | Asi Haviv | Treatment of lupus arthritis using laquinimod |
| PL2609086T3 (en) | 2010-08-27 | 2015-07-31 | Gruenenthal Gmbh | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators |
| MX2013000748A (en) | 2010-08-27 | 2013-03-05 | Gruenenthal Gmbh | Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators. |
| KR20130100300A (en) | 2010-08-27 | 2013-09-10 | 그뤼넨탈 게엠베하 | Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators |
| BR112013005056A2 (en) | 2010-09-01 | 2016-05-31 | Gruenenthal Gmbh | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as modulators kcnq2 / 3 |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| SG11201401330YA (en) | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| EP2819670B1 (en) | 2012-02-27 | 2026-05-20 | Vertex Pharmaceuticals Incorporated | Pharmaceutical preparations and their administration |
| TW201400117A (en) | 2012-06-05 | 2014-01-01 | Teva Pharma | Treatment of ocular inflammation with laquinimod |
| EA201590788A1 (en) | 2012-11-07 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | AMINAL SALTS LACHINIMODA |
| JP2016514162A (en) | 2013-03-14 | 2016-05-19 | テバ ファーマシューティカル インダストリーズ リミティド | Laquinimod sodium crystals and improved process for their production |
| CN103319403B (en) * | 2013-05-10 | 2016-03-30 | 重庆理工大学 | Own quinoline ketone of a kind of neonate tumour blood vessel inhibitor and its production and use |
| CN103664777A (en) * | 2013-10-09 | 2014-03-26 | 重庆理工大学 | 2-undecyl-3-methyl-hydroxyl-quinoline compound as well as preparation method, pharmaceutical composition and use thereof |
| HK1231413A1 (en) | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| EP3041472B1 (en) * | 2014-09-23 | 2017-02-01 | Active Biotech AB | Quinoline carboxamides for use in the treatment of multiple myeloma |
| CA2963945C (en) | 2014-10-07 | 2023-01-10 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| CA3241699A1 (en) * | 2021-12-20 | 2023-06-29 | The Johns Hopkins University | Compounds for treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| GB9108547D0 (en) | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| GB9404378D0 (en) | 1994-03-07 | 1994-04-20 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| GB2290786A (en) | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| SE9802549D0 (en) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
-
2000
- 2000-10-24 PL PL354540A patent/PL199781B1/en unknown
- 2000-10-24 RS YUP-232/02A patent/RS51019B/en unknown
- 2000-10-24 CN CNB008147574A patent/CN100390148C/en not_active Expired - Fee Related
- 2000-10-24 US US09/694,757 patent/US6395750B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| RS51019B (en) | 2010-10-31 |
| CN1589264A (en) | 2005-03-02 |
| US6395750B1 (en) | 2002-05-28 |
| YU23202A (en) | 2004-11-25 |
| CN100390148C (en) | 2008-05-28 |
| PL199781B1 (en) | 2008-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6048201A (en) | Quinazoline derivatives for the treatment of tumours | |
| HUP0400314A3 (en) | Pharmaceutical combinations for the treatment of cancer | |
| HUP0203238A3 (en) | Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them | |
| SI1176964T1 (en) | Uses of et743 for treating cancer | |
| HUP0500424A2 (en) | Combination therapy for the treatment of cancer | |
| IL148579A0 (en) | Oncolytic combinations for the treatment of cancer | |
| AU2508597A (en) | Drug for the treatment of tumours | |
| AU6062900A (en) | Substituted indole compounds and their use for the treatment of cancer | |
| HUP0200805A2 (en) | Improved cancer treatment with temozolomide | |
| ZA200110436B (en) | Therapeutic use of melatonin. | |
| AU4369800A (en) | Treatment of metastatic cancer through mts-1 gene | |
| HUP0101947A3 (en) | Combination for the treatment of tumors | |
| ZA200108256B (en) | Compositions and methods for the treatment and diagnosis of breast cancer. | |
| HUP0200825A2 (en) | Compositions and methods for the treatment and diagnosis of breast cancer | |
| HUP0300772A3 (en) | Medicament for the immunotherapy of malignant tumours | |
| ZA200203166B (en) | Treatment of cancer. | |
| AU5552400A (en) | Treatment of cancer | |
| HUP0001891A2 (en) | Medicament for the treatment of migraine | |
| ZA984650B (en) | Intratumoral administration of triphenylethylenes for the treatment of cancer | |
| GB9911183D0 (en) | Treatment of cancers | |
| GB9927106D0 (en) | Cancer treatment | |
| GB9908176D0 (en) | Cancer treatment | |
| GB9927005D0 (en) | Treatment of cancers | |
| GB9911346D0 (en) | Treatment of cancers | |
| GB9918534D0 (en) | Treatment of cancers |